apceth receives manufacturer licence for somatic cell therapeutics

The research work is focused to develop stem cell and gene therapies to treat benign and malignant diseases.

apceth CEO Christine Gunther said the manufacturer’s licence has been issued by the Government of Upper Bavaria and the Paul-Ehrlich-Institute.

"we joined forces with the authorities to develop stringent guidelines to ensure that stem cell therapeutics will also fulfil the highest quality demands in the future", Gunther said.

Apceth MD and CFO Helmut Jeggle said the licence not only enables them to produce somatic cell pharmaceuticals for their own needs, but also to take on their partners’ development projects.